Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Pritelivir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aicuris Reveals Pritelivir Phase 2 Success And AIC468 Safety Data
    Aicuris Reveals Pritelivir Phase 2 Success And AIC468 Safety Data

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169156/0/en/Aicuris-Presents-Positive-Phase-2-Results-for-Pritelivir-and-Favorable-Phase-1-Safety-Data-for-AIC468-at-ID-Week-2025.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    Aicuris’ Pritelivir Meets Ph3 Endpoint in Refractory HSV
    Aicuris’ Pritelivir Meets Ph3 Endpoint in Refractory HSV

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167679/0/en/Aicuris-Announces-Pritelivir-Met-Primary-Endpoint-in-Immunocompromised-Patients-with-Refractory-Herpes-Simplex-Virus-in-Phase-3-Pivotal-Trial.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Aicuris to Present Orally and via Poster at ID Week 2025
    Aicuris to Present Orally and via Poster at ID Week 2025

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150566/0/en/Aicuris-Announces-Upcoming-Oral-and-Poster-Presentations-at-ID-Week-2025.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    Aicuris Completes Enrollment for Pritelivir Herpes Trial
    Aicuris Completes Enrollment for Pritelivir Herpes Trial

    24 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/24/3120818/0/en/Aicuris-Enrolled-Last-Participant-in-Pivotal-Trial-with-Pritelivir-to-Treat-Refractory-Herpes-Simplex-Infection-in-Immunocompromised-Patients.html

    GLOBENEWSWIRE
    24 Jul 2025
    Share Share
    AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir
    AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir

    06 Jun 2020

    // APNEWS

    https://apnews.com/fbb951ff5cc252c651f6a300e45c2365

    APNEWS
    06 Jun 2020
    Share Share